IMPLANTS WITH CONTROLLED DRUG DELIVERY FEATURES AND METHODS OF USING SAME
First Claim
Patent Images
1. A drug delivery ocular implant comprising:
- an outer shell having a proximal end, a distal end, said outer shell being shaped to define an interior lumen;
at least a first active drug positioned within said interior lumen;
a cap configured for reversible interaction with the proximal end of said outer shell,wherein said cap comprises at least one aperture;
a membrane positioned between said cap and said proximal end of said outer shell,wherein said membrane is permeable to said at least a first active drug,wherein said membrane is dimensioned based on the permeability of said membrane to said at least a first active drug and the desired duration of elution of said first active drug,wherein upon placement of the cap over the proximal end of the outer shell, said membrane is retained between said cap and said proximal end,wherein said membrane occludes said at least one aperture, thereby allowing elution of said at least a first active drug to occur only through said membrane;
at least one fluid inflow pathway and one fluid outflow pathway positioned adjacent the distal end of said outer shell,wherein said at least one fluid inflow pathway and one fluid outflow pathway are configured to deliver ocular fluid to a physiological outflow pathway; and
a retention protrusion on the distal end of said outer shell, wherein said retention protrusion is configured to anchor the ocular implant at a target tissue site.
1 Assignment
0 Petitions
Accused Products
Abstract
Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.
-
Citations
14 Claims
-
1. A drug delivery ocular implant comprising:
-
an outer shell having a proximal end, a distal end, said outer shell being shaped to define an interior lumen; at least a first active drug positioned within said interior lumen; a cap configured for reversible interaction with the proximal end of said outer shell, wherein said cap comprises at least one aperture; a membrane positioned between said cap and said proximal end of said outer shell, wherein said membrane is permeable to said at least a first active drug, wherein said membrane is dimensioned based on the permeability of said membrane to said at least a first active drug and the desired duration of elution of said first active drug, wherein upon placement of the cap over the proximal end of the outer shell, said membrane is retained between said cap and said proximal end, wherein said membrane occludes said at least one aperture, thereby allowing elution of said at least a first active drug to occur only through said membrane; at least one fluid inflow pathway and one fluid outflow pathway positioned adjacent the distal end of said outer shell, wherein said at least one fluid inflow pathway and one fluid outflow pathway are configured to deliver ocular fluid to a physiological outflow pathway; and a retention protrusion on the distal end of said outer shell, wherein said retention protrusion is configured to anchor the ocular implant at a target tissue site. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8)
-
-
9. A drug delivery ocular implant comprising:
-
an elongate outer shell having a proximal end, a distal end, said outer shell being shaped to define an interior lumen; at least a first active drug positioned within said interior lumen; at least one fluid flow pathway running from a proximal region of the outer shell to a more distal region of the outer shell, wherein said at least one fluid flow pathway is configured to deliver ocular fluid to a physiological outflow pathway; a valve positioned at the distal-most end of the outer shell, wherein said valve is reversibly openable to enable passage of the at least a first active drug from said interior lumen to a target site external to said implant. - View Dependent Claims (10, 11, 12, 13, 14)
-
Specification